Skip to main content
. 2017 Feb 16;8(20):33922–33932. doi: 10.18632/oncotarget.15412

Figure 4. Meta-analysis of the prognosis of circulating EGFR mutations for OS.

Figure 4

A. Forest plots of HR and 95% CI in advanced NSCLC patients. Only marginally statistically significant OS (HR = 0.77, 95% CI 0.54-1.10) was observed between NSCLC patients with and without circulating EGFR mutations; B. results of sensitive analysis showed that there was no “dominant” study driving the results of the meta-analysis; C. forest plots of HR and 95% CI in advanced NSCLC patients treated by EGFR-TKIs, there was no statistical significance between patients with and without circulating EGFR mutations (HR = 0.79, 95% CI 0.52-1.21, p = 0.15).